OPTIMAAL

OPTIMAAL

Cardiology A clinical trial–Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. See Losartan.
Mentioned in ?
References in periodicals archive ?
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart-failure after an acute myocardial infarction: results from the OPTIMAAL study.
Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee of the OPTIMAAL Study Group.
But the most impressive finding in the OPTIMAAL analysis was that among patients who survived at least 30 days after a stroke, 33% were fully recovered with no disability at the 1month mark and another 39% had minor disability with respect to the domains of speech, vision, walking, and self-care, as rated by clinical investigators.
In OPTIMAAL, COZAAR was neither superior nor non-inferior to captopril in reducing all-cause mortality in patients with acute MI, with a non-significant difference in favor of captopril.
coordinator of the OPTIMAAL steering committee and professor of medicine at the University of Bergen, Bergen, Norway.
The OPTIMAAL study assessed an investigational use of COZAAR.
OPTIMAAL fingered the ACE inhibitor as first-line therapy in this setting, based upon the finding of a nonsignificant trend toward lower mortality: 16% as compared with 18% with losartan after a mean follow-up of 2.
On the other hand, losartan is a reasonable option in ACE inhibitor-intolerant patients based upon the OPTIMAAL finding that the angiotensin receptor blocker was significantly better tolerated than captopril.
Merck continues to support the growth of COZAAR and HYZAAR with ongoing investment in two large outcomes studies, LIFE and OPTIMAAL.
Merck continues to support the growth of Cozaar & Hyzaar with ongoing investments in two large outcomes studies, LIFE and OPTIMAAL.